UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
December 17, 2021
(Date of Report - date of earliest event reported)
InMed Pharmaceuticals Inc.
(Exact Name of Registrant as Specified in Its Charter)
| British Columbia | | 001-39685 | | 98-1428279 |
(State or Other Jurisdiction of Incorporation or Organization) | | (Commission File Number) | | (I.R.S. Employer Identification No.) |
Suite 310 – 815 W. Hastings Street Vancouver, B.C., Canada | | V6C 1B4 |
| (Address of Principal Executive Offices) | | (Zip Code) |
(604) 669-7207
(Registrant's Telephone Number, Including Area Code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | | Trading Symbol(s) | | Name of each exchange on which registered |
| Common Shares, no par value | | INM | | The Nasdaq Stock Market |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 5.07: Submission of Matters to a Vote of Security Holders
On December 17, 2021, InMed Pharmaceuticals Inc., or the “Corporation”, held its Annual General Meeting of Shareholders. At the meeting, shareholders voted in favor of all items of business, as indicated below:
Proposal No. 1—Election of Directors
The Corporation’s shareholders voted to elect the following persons to the board of directors of the Corporation, each to serve until the 2022 Annual General Meeting:
| Nominee | | Votes For | | | % Votes For | | | Votes Withheld | | | %Votes Withheld | | | Broker Non-Votes | |
| Eric A. Adams | | | 2,960,270 | | | | 93.98 | | | | 189,717 | | | | 6.02 | | | | 2,821,286 | |
| Adam Cutler | | | 2,980,880 | | | | 94.63 | | | | 169,107 | | | | 5.37 | | | | 2,821,286 | |
| William J. Garner | | | 2,957,803 | | | | 93.90 | | | | 192,184 | | | | 6.10 | | | | 2,821,286 | |
| Andrew Hull | | | 2,980,096 | | | | 94.61 | | | | 169,891 | | | | 5.39 | | | | 2,821,286 | |
| Catherine Sazdanoff | | | 2,902,565 | | | | 92.14 | | | | 247,422 | | | | 7.86 | | | | 2,821,286 | |
Proposal No. 2—Appointment of Independent Registered Public Accounting Firm
The Corporation’s shareholders voted to approve the appointment of KPMG LLP as the independent registered public accounting firm of the Corporation until the next annual shareholders’ meeting or until a successor is named.
| Votes For | | | % Votes For | | | Vote Against | | | % Votes Against | | | Abstain | | | Broker Non-Votes | |
| | 5,787,855 | | | | 96.93 | | | | 0 | | | | 0.00 | | | | 183,418 | | | | 0 | |
Item 9.01 Exhibits.
(d) Exhibits.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: December 17, 2021
| | INMED PHARMACEUTICALS INC. |
| | | |
| | By: | /s/ Bruce Colwill |
| | Name: | Bruce Colwill |
| | Title: | Chief Financial Officer |
2
